VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2020 | MAGNOLIA trial: zanubrutinib for MZL

Stephen Opat, FRACP, FRCPA, MBBS, Monash University, Melbourne, Australia, shares the findings of the Phase II MAGNOLIA trial (NCT03846427) evaluating the safety and efficacy of a next-generation Bruton’s tyrosine kinase inhibitor, zanubrutinib, in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL). After 10 months, zanubrutinib has been shown to be efficacious, with a 74% overall response rate (ORR) and rates expected to increase with longer follow-up. The clinical benefits seen with zanubrutinib use extended to various MZL subtypes including extranodal, nodal, and splenic. A favorable safety profile was observed, with the most common adverse event being neutropenia. Follow-up is ongoing to improve understanding of the durability of responses. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.


Research payments to institution: Beigene

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter